{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:14:02Z","timestamp":1792030442123,"version":"4.4.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00398073"],"award-info":[{"award-number":["RS-2024-00398073"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-00563140"],"award-info":[{"award-number":["RS-2025-00563140"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"'la Caixa' Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019179","name":"La Caixa Foundation","doi-asserted-by":"publisher","award":["HR20-00584"],"award-info":[{"award-number":["HR20-00584"]}],"id":[{"id":"10.13039\/501100019179","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijpddr.2026.100651","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:35:53Z","timestamp":1778762153000},"page":"100651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["In vitro profiling of Trypanosoma cruzi inhibitors identified from High throughput Screening and application to parasite painting"],"prefix":"10.1016","volume":"31","author":[{"given":"Kyung-Hwa","family":"Baek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeryon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sooyoung","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4202-1219","authenticated-orcid":false,"given":"Olga","family":"Genilloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Robert","family":"Ioset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Hwan","family":"No","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijpddr.2026.100651_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0003493","article-title":"Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line","volume":"9","author":"Alonso-Padilla","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"8","key":"10.1016\/j.ijpddr.2026.100651_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0001298","article-title":"Activity in vivo of anti-trypanosoma cruzi compounds selected from a high throughput screening","volume":"5","author":"Andriani","year":"2011","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"1","key":"10.1016\/j.ijpddr.2026.100651_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1087057114555846","article-title":"High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and chagas disease","volume":"20","author":"Annang","year":"2015","journal-title":"J. Biomol. Screen"},{"issue":"5","key":"10.1016\/j.ijpddr.2026.100651_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pathogens9050393","article-title":"Infectivity and drug susceptibility profiling of of different leishmania-host cell combinations","volume":"9","author":"Baek","year":"2020","journal-title":"Pathogens"},{"issue":"9394","key":"10.1016\/j.ijpddr.2026.100651_bib6","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(03)14694-6","article-title":"The trypanosomiases","volume":"362","author":"Barrett","year":"2003","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ijpddr.2026.100651_bib7","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.298.18.2171","article-title":"Evaluation and treatment of chagas disease in the United StatesA systematic review","volume":"298","author":"Bern","year":"2007","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ijpddr.2026.100651_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8040472","article-title":"High-throughput screening of the ReFRAME library identifies potential drug repurposing candidates for Trypanosoma cruzi","volume":"8","author":"Bernatchez","year":"2020","journal-title":"Microorganisms"},{"issue":"2","key":"10.1016\/j.ijpddr.2026.100651_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000384","article-title":"Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening","volume":"3","author":"Bettiol","year":"2009","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"9","key":"10.1016\/j.ijpddr.2026.100651_bib10","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/nprot.2016.105","article-title":"Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes","volume":"11","author":"Bray","year":"2016","journal-title":"Nat. Protoc."},{"issue":"11","key":"10.1016\/j.ijpddr.2026.100651_bib11","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1128\/AAC.40.11.2592","article-title":"Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing \u03b2-galactosidase","volume":"40","author":"Buckner","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ijpddr.2026.100651_bib12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/17460441.2011.573782","article-title":"Methodological advances in drug discovery for Chagas disease","volume":"6","author":"Bustamante","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"issue":"7","key":"10.1016\/j.ijpddr.2026.100651_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000740","article-title":"In Vitro and in Vivo High-throughput assays for the testing of anti-trypanosoma cruzi compounds","volume":"4","author":"Canavaci","year":"2010","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"41","key":"10.1016\/j.ijpddr.2026.100651_bib14","doi-asserted-by":"crossref","first-page":"14715","DOI":"10.1002\/anie.201907853","article-title":"Design, synthesis, and phenotypic profiling of pyrano-furo-pyridone pseudo natural products","volume":"58","author":"Christoforow","year":"2019","journal-title":"Angew. Chem., Int. Ed."},{"issue":"7","key":"10.1016\/j.ijpddr.2026.100651_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001777","article-title":"A simple strain typing assay for Trypanosoma cruzi: discrimination of major evolutionary lineages from a single amplification product","volume":"6","author":"Cosentino","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"1","key":"10.1016\/j.ijpddr.2026.100651_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1590\/S0074-02762002000100001","article-title":"A critical review on chagas disease chemotherapy","volume":"97","author":"Coura","year":"2002","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"1","key":"10.1016\/j.ijpddr.2026.100651_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36829-x","article-title":"Reference compounds for characterizing cellular injury in high-content cellular morphology assays","volume":"14","author":"Dahlin","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ijpddr.2026.100651_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1021\/ml400403u","article-title":"Diversity-oriented synthesis yields a new drug lead for treatment of chagas disease","volume":"5","author":"Dandapani","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.ijpddr.2026.100651_bib19","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1128\/AAC.01777-09","article-title":"Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease","volume":"54","author":"Engel","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ijpddr.2026.100651_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S0037-86822007000100001","article-title":"Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe City (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution","volume":"40","author":"Fabbro","year":"2007","journal-title":"Rev. Soc. Bras. Med. Trop."},{"issue":"NOV","key":"10.1016\/j.ijpddr.2026.100651_bib21","first-page":"1","article-title":"Trypanosoma cruzi extracellular amastigotes and host cell signaling: more pieces to the puzzle","volume":"3","author":"Ferreira","year":"2012","journal-title":"Front. Immunol."},{"issue":"30","key":"10.1016\/j.ijpddr.2026.100651_bib22","doi-asserted-by":"crossref","first-page":"12470","DOI":"10.1002\/anie.202000364","article-title":"Phenotyping reveals targets of a pseudo-natural-product autophagy inhibitor","volume":"59","author":"Foley","year":"2020","journal-title":"Angew. Chem., Int. Ed."},{"issue":"8","key":"10.1016\/j.ijpddr.2026.100651_bib23","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1128\/AAC.00520-15","article-title":"Limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging","volume":"59","author":"Francisco","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"September","key":"10.1016\/j.ijpddr.2026.100651_bib24","first-page":"1","article-title":"Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage","volume":"6","author":"Francisco","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ijpddr.2026.100651_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/tropicalmed4020082","article-title":"Drug discovery for chagas disease: impact of different host cell lines on assay performance and hit compound selection","volume":"4","author":"Franco","year":"2019","journal-title":"Trop. Med. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijpddr.2026.100651_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-22174-4","article-title":"Natural product fragment combination to performance-diverse pseudo-natural products","volume":"12","author":"Grigalunas","year":"2021","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.ijpddr.2026.100651_bib27","doi-asserted-by":"crossref","first-page":"13088","DOI":"10.1074\/jbc.M111.230847","article-title":"Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites","volume":"286","author":"Hall","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ijpddr.2026.100651_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.05135-11","article-title":"Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.ijpddr.2026.100651_bib29","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/2472555220917115","article-title":"High-Content phenotypic profiling in esophageal adenocarcinoma identifies selectively active pharmacological classes of drugs for repurposing and chemical starting points for novel drug discovery","volume":"25","author":"Hughes","year":"2020","journal-title":"SLAS Discovery"},{"issue":"1","key":"10.1016\/j.ijpddr.2026.100651_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1087057114553103","article-title":"Lead identification to clinical candidate selection: drugs for chagas disease","volume":"20","author":"Jeffrey Neitz","year":"2015","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.ijpddr.2026.100651_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.91362","article-title":"High-content microscopy reveals a morphological signature of bortezomib resistance","volume":"12","author":"Kelley","year":"2023","journal-title":"eLife"},{"issue":"4","key":"10.1016\/j.ijpddr.2026.100651_bib32","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0026-895X(25)09018-2","article-title":"Characterization of the effects of a new Ca2+ channel activator, FPL 64176, in GH3 cells","volume":"42","author":"Kunze","year":"1992","journal-title":"Mol. Pharmacol."},{"issue":"14","key":"10.1016\/j.ijpddr.2026.100651_bib33","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1002\/anie.201913712","article-title":"Image-Based morphological profiling identifies a lysosomotropic, iron-sequestering autophagy inhibitor","volume":"59","author":"Laraia","year":"2020","journal-title":"Angew. Chem., Int. Ed."},{"issue":"6","key":"10.1016\/j.ijpddr.2026.100651_bib34","first-page":"1","article-title":"Chagas disease: from discovery to a worldwide health problem","volume":"49","author":"Lidani","year":"2019","journal-title":"J. Phys. Oceanogr."},{"issue":"9","key":"10.1016\/j.ijpddr.2026.100651_bib35","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1002\/anie.202013731","article-title":"Design, synthesis, and biological evaluation of chemically and biologically diverse pyrroquinoline pseudo natural products","volume":"60","author":"Liu","year":"2021","journal-title":"Angew. Chem., Int. Ed."},{"issue":"7","key":"10.1016\/j.ijpddr.2026.100651_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0006612","article-title":"Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery","volume":"12","author":"MacLean","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"9","key":"10.1016\/j.ijpddr.2026.100651_bib37","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.106.624296","article-title":"Pathogenesis of chronic Chagas heart disease","volume":"115","author":"Marin-Neto","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijpddr.2026.100651_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2008.04.001","article-title":"Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT)","volume":"156","author":"Marin-Neto","year":"2008","journal-title":"Am. Heart J."},{"issue":"6","key":"10.1016\/j.ijpddr.2026.100651_bib39","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/acsinfecdis.2c00123","article-title":"An updated view of the Trypanosoma cruzi life cycle: intervention points for an effective treatment","volume":"8","author":"Mart\u00edn-Escolano","year":"2022","journal-title":"ACS Infect. Dis."},{"issue":"36","key":"10.1016\/j.ijpddr.2026.100651_bib40","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2105815118","article-title":"Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19","volume":"118","author":"Mirabelli","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"10","key":"10.1016\/j.ijpddr.2026.100651_bib41","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1128\/AAC.04660-14","article-title":"Toxic profile of benznidazole in patients with chronic chagas disease: risk factors and comparison of the product from two different manufacturers","volume":"59","author":"Molina","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ijpddr.2026.100651_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087188","article-title":"An image-based algorithm for precise and accurate high throughput assessment of drug activity against the human parasite Trypanosoma cruzi","volume":"9","author":"Moon","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpddr.2026.100651_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep04703","article-title":"Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development","volume":"4","author":"Moraes","year":"2014","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.ijpddr.2026.100651_bib44","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","article-title":"Benznidazole and posaconazole in eliminating parasites in asymptomatic T. Cruzi carriers: the STOP-CHAGAS trial","volume":"69","author":"Morillo","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ijpddr.2026.100651_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-37570-1","article-title":"Predicting compound activity from phenotypic profiles and chemical structures","volume":"14","author":"Moshkov","year":"2023","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.ijpddr.2026.100651_bib46","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/PL00008532","article-title":"Setting of a colorimetric method to determine the viability of Trypanosoma cruzi epimastigotes","volume":"86","author":"Muelas-Serrano","year":"2000","journal-title":"Parasitol. Res."},{"issue":"7","key":"10.1016\/j.ijpddr.2026.100651_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001253","article-title":"A screen against leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit","volume":"5","author":"De Muylder","year":"2011","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"5","key":"10.1016\/j.ijpddr.2026.100651_bib48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0035-9203(88)90208-8","article-title":"Comparative studies of drug susceptibility of five strains of trypanosoma cruzi in vivo and in vitro","volume":"82","author":"Neal","year":"1988","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2026.100651_bib49","series-title":"Optimization and Biological Validation of an in Vitro Assay Using the Transfected Dm28c\/pLacZ Trypanosoma cruzi Strain","first-page":"1","author":"Nicola","year":"2021"},{"key":"10.1016\/j.ijpddr.2026.100651_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/srep08771","article-title":"New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource","volume":"5","author":"Pe\u00f1a","year":"2015","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.ijpddr.2026.100651_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002977","article-title":"Synergy testing of FDA-Approved drugs identifies potent drug combinations against Trypanosoma cruzi","volume":"8","author":"Planer","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"9723","key":"10.1016\/j.ijpddr.2026.100651_bib54","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(10)60061-X","article-title":"Chagas disease","volume":"375","author":"Rassi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2026.100651_bib55","first-page":"1","volume":"vol. 10","author":"Resende","year":"2020"},{"issue":"2","key":"10.1016\/j.ijpddr.2026.100651_bib56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00436-006-0126-y","article-title":"Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes","volume":"99","author":"Rol\u00f3n","year":"2006","journal-title":"Parasitol. Res."},{"issue":"2","key":"10.1016\/j.ijpddr.2026.100651_bib57","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0014-4894(88)90091-4","article-title":"Trypanosoma cruzi: an in vitro cycle of cell differentiation in axenic culture","volume":"66","author":"Rondinelli","year":"1988","journal-title":"Exp. Parasitol."},{"issue":"4","key":"10.1016\/j.ijpddr.2026.100651_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0004584","article-title":"Identification of trypanocidal activity for known clinical compounds using a new Trypanosoma cruzi hit-discovery screening Cascade","volume":"10","author":"De Rycker","year":"2016","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"12","key":"10.1016\/j.ijpddr.2026.100651_bib59","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.chembiol.2021.06.003","article-title":"Combined morphological and proteome profiling reveals target-independent impairment of cholesterol homeostasis","volume":"28","author":"Schneidewind","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"3","key":"10.1016\/j.ijpddr.2026.100651_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2025.116998","article-title":"Scenario of Acute Chagas Disease in Brazil: a spatio-temporal analysis","volume":"113","author":"da Silva","year":"2025","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ijpddr.2026.100651_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001671","article-title":"An image-based high-content screening assay for compounds targeting intracellular leishmania donovani amastigotes in human macrophages","volume":"6","author":"Siqueira-Neto","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"10","key":"10.1016\/j.ijpddr.2026.100651_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0009870","article-title":"Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay","volume":"15","author":"Svensen","year":"2021","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"7","key":"10.1016\/j.ijpddr.2026.100651_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms10071287","article-title":"Temporal and wash-out studies identify medicines for malaria venture pathogen box compounds with fast-acting activity against both Trypanosoma cruzi and Trypanosoma brucei","volume":"10","author":"Sykes","year":"2022","journal-title":"Microorganisms"},{"issue":"20","key":"10.1016\/j.ijpddr.2026.100651_bib64","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1021\/jm4004279","article-title":"Approaches to protozoan drug discovery: phenotypic screening","volume":"56","author":"Sykes","year":"2013","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ijpddr.2026.100651_bib65","first-page":"215","article-title":"Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes","volume":"5","author":"Sykes","year":"2015","journal-title":"Int. J. Parasitol.: Drugs Drug Resist."},{"issue":"4","key":"10.1016\/j.ijpddr.2026.100651_bib66","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","article-title":"Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial","volume":"18","author":"Torrico","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.ijpddr.2026.100651_bib67","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00436-005-1300-3","article-title":"A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing \u03b2-galactosidase","volume":"95","author":"Vega","year":"2005","journal-title":"Parasitol. Res."},{"issue":"9","key":"10.1016\/j.ijpddr.2026.100651_bib68","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1091\/mbc.E20-12-0784","article-title":"Predicting cell health phenotypes using image-based morphology profiling","volume":"32","author":"Way","year":"2021","journal-title":"Mol. Biol. Cell"},{"issue":"8","key":"10.1016\/j.ijpddr.2026.100651_bib70","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/acsinfecdis.5b00068","article-title":"In vitro and in vivo activity of multitarget inhibitors against Trypanosoma brucei","volume":"1","author":"Yang","year":"2015","journal-title":"ACS Infect. Dis."},{"issue":"2","key":"10.1016\/j.ijpddr.2026.100651_bib71","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/1087057116673796","article-title":"Evaluation of parameters impacting drug susceptibility in intracellular Trypanosoma cruzi assay protocols","volume":"22","author":"Yang","year":"2017","journal-title":"SLAS Discovery"},{"issue":"6","key":"10.1016\/j.ijpddr.2026.100651_bib72","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1590\/0074-0276140156","article-title":"Drug discovery for chagas disease should consider Trypanosoma cruzi strain diversity","volume":"109","author":"Zingales","year":"2014","journal-title":"Mem. Inst. Oswaldo Cruz"}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320726000217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320726000217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:42:11Z","timestamp":1788450131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320726000217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":68,"alternative-id":["S2211320726000217"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2026.100651","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro profiling of Trypanosoma cruzi inhibitors identified from High throughput Screening and application to parasite painting","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2026.100651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}],"article-number":"100651"}}